Skin Test for Parkinson's Risk in People With Essential Tremor
Uses skin biopsies to look for Parkinson's-related protein in people with essential tremor.
Plain-language title generated from the registry record
Registry title: Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Key facts
- Where
- Farmington Hills, Houston, Irvine, Kansas City, Los Angeles, Louisville, Memphis, Nashville, Orlando, and Scottsdale, United StatesSee the 11 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 85 with essential tremor or essential tremor-plus. It uses a skin biopsy to look for a protein linked to early Parkinson's disease.
- Age
- 50 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Essential tremor (tremor in both arms during movement, for at least 3 years, with no other nerve signs) or essential tremor-plus (essential tremor with extra mild nerve signs).
- Earlier treatment
- Cannot be on blood-thinning treatment (anticoagulant or dual anti-platelet therapy) or on carbidopa-levodopa for Parkinson's disease. Cannot have had a brain procedure to treat tremor, such as deep brain stimulation or focused ultrasound thalamotomy.
- Biomarker or test result
- An abnormal DaTscan means a person cannot join.
Main reasons for not taking part
- Another nerve-degenerating disease, or other nerve damage signs
- Abnormal DaTscan
- Severe blood vessel disease in the limbs, or active heart or brain blood vessel disease
- Poor wound healing, scarring or keloid history, or allergy to local anesthesia
- Tremor only in the head or voice, or tremor only during one task
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT07428447, who can take part
Where in United States
- QUEST Research InstituteFarmington Hills, United StatesContact: Denise MorgottTaking people
- Baylor College of MedicineHouston, United StatesContact: Haneyeh Primary Research CoordinatorTaking people
- University of California Irvine HealthIrvine, United StatesContact: Shivani VenkateswaranNot yet recruiting
- University of Kansas Medical CenterKansas City, United StatesContact: Kim Lee, Clinical Research CoordinatorTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Michele Lima Gregorio, PhDNot yet recruiting
- Norton HealthcareLouisville, United StatesContact: Andrea J Gambrell, RN, BSN, CCMTaking people
- Veracity Neurosciences LLCMemphis, United StatesContact: Hannah TouliatosTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Jackie Harris, RMA, CTRC IVNot yet recruiting
- Neurology OneOrlando, United StatesContact: Jinna Santiago, RN, CRCTaking people
- CND Clinical Research CenterScottsdale, United StatesContact: Jeannie Director of Clinical ResearchTaking people
- Movement Disorders Center of ArizonaScottsdale, United StatesContact: Danica EvidenteTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- CND Life Sciences
- Trial code
- NCT07428447
- Record updated
- 10 November 2026
- Original description
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies.Read full original descriptionShow less
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies.
Primary Objectives
1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD
Inclusion: Age 50-85 years old; Diagnosis of ET as defined by the 2018 MDS Task force paper "1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism." OR; Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, "Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here."; Willing to participate in all study procedures; Able and willing to provide written informed consent.
Exclusion: Participant is currently receiving treatment with carbidopa-levodopa for PD; Prior to enrollment, receipt of an intracranial procedure intended to treat tremor or parkinsonism, including thalamic deep brain stimulation (DBS) implantation or focused ultrasound (FUS) thalamotomy. Other prior intracranial surgery is exclusionary only when, in the investigator's or Sponsor's Chief Medical Officer's judgment, it could materially affect motor assessments, diagnostic classification, participant safety, or interpretation of study outcomes; Clinical evidence of severe peripheral vascular disease; Clinically active coronary artery or cerebrovascular disease; Allergic reaction to local anesthesia; History of or increased risk for impaired wound healing, scarring, or keloid formation; History of other neurodegenerative disorder or evidence of neurological co-pathology; Participant is currently on anticoagulant or dual anti-platelet therapy; Under age 50, Over age 85; Alcoholism; Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise; Abnormal DaTscan; Isolated focal tremors (head, voice); Task-specific tremor (e.g., primary writing tremor); Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET; Sudden onset and step-wise deterioration.